A--(PEB) Agilent Technologies and PE Biosystems Announce Marketing and Product Development Agreement for LC/MS Systems
BUSINESS WIRE - March 13, 2000 03:17
PALO ALTO, Calif., Mar 13, 2000 (BUSINESS WIRE) -- Agilent Technologies Inc. (NYSE:A) and PE Biosystems Group (NYSE:PEB) -- a PE Corporation business including its PE SCIEX joint venture -- today announced that they have signed a cooperative agreement to provide pharmaceutical researchers with a full range of liquid chromatography (LC) and mass spectrometry (MS) solutions.
The purpose of the relationship is to enable solutions for customers, which could not be achieved by either company separately, through access to the product portfolios and sales/marketing strengths of both Agilent and PE Biosystems. Financial terms of the agreement were not disclosed.
The two companies bring their respective LC and MS expertise to this relationship, providing otherwise unavailable LC/MS solutions through the integration of Agilent and PE Biosystems technologies. This agreement follows an OEM agreement implemented in October 1999, whereby PE Biosystems will sell, install and become the first point of contact for service support of Agilent Technologies' LC components integrated with their MS products.
Major product platforms included in this agreement include the industry-leading Agilent 1100 Series LC Systems Platform, Agilent LC/MSD Single-Quad Systems, Agilent's new 1100 Series LC/MS Ion-Trap System, PE Biosystems/PE SCIEX API 3000 LC/MS/MS Triple-Quad System, QSTAR Pulsar LC/MS/MS system and the PE Biosystems Mariner API-TOP Workstation.
Further details of the agreement include the following:
Hardware
Agilent Technologies will provide PE Biosystems with the industry-leading 1100 Series LC Systems for integration with PE Biosystems/PE SCIEX mass spectrometers. PE Biosystems will sell, install, support and service these platforms. The two companies will cooperate to deliver new analytical HPLC technologies with increased throughput, including the new 1100 Series Capillary LC System and 96-well plate samplers.
Software
The strengths of Agilent chromatography software will be combined and integrated with the power of PE Biosystems' MS software. As a first step, data generated on the Agilent LC/MSD system will be made compatible with PE SCIEX Analyst software for data reduction and evaluation.
Support
Agilent Technologies and PE Biosystems will work to ensure superior customer support for their pharmaceutical clients. Both companies will cooperate to ensure that customers are supplied with the optimum solution to their LC/MS system needs.
"To increase our customers' R&D success, PE Biosystems is focused on providing instrument and information systems that enable R&D groups to generate, manage, understand, and use high-quality, data-rich information," said Michael Hunkapiller, Ph.D., president of PE Biosystems. "Agilent Technologies is an innovative, forward-looking company with strengths that are complementary to ours. Together we can more rapidly and efficiently meet our customers' needs for integrated analysis and informatics."
"We are very pleased to be entering into this agreement with the recognized leader in the bio-instrumentation field," said Richard (Rick) D. Kniss, senior vice president and general manager of Agilent's Chemical Analysis Group. "This agreement builds upon the unique strengths of both companies to synergistically deliver a more complete range of solutions of important analytical techniques to improve productivity in the drug discovery and development process. Pharmaceutical research chemists will now have access to a greater range of advanced analytical tools and services for the rapid assessment of lead compounds as likely drug candidates."
Information about Agilent's chemical analysis products and services can be found on the Web at www.agilent.com/chem.
About PE Corporation
PE Corporation currently comprises two operating groups. The PE Biosystems Group (NYSE:PEB), with sales of $1.2 billion during fiscal 1999, develops and markets instrument-based systems, reagents, software, and contract-related services to the life science and research community. PE Biosystems, which is headquartered in California, includes four divisions: Applied Biosystems, PE Informatics, Tropix, and PerSeptive Biosystems. PE SCIEX, which is managed through the PerSeptive Biosystems Division, is a joint venture between PE Corporation and MDS SCIEX, the instrumentation technology division of MDS, Inc. Celera Genomics Group (NYSE:CRA), a newly formed business unit located in Rockville, Maryland, intends to become the definitive source of genomic and related medical information. Information about the Company is available on the worldwide web at www.pe-corp.com or by phoning 1-800-762-6923.
About Agilent Technologies
Agilent Technologies, Inc. (NYSE:A) is a diversified technology company, resulting from Hewlett-Packard Company's plan to strategically realign itself into two fully independent companies. With 42,000 employees serving customers in more than 120 countries, Agilent Technologies is a global leader in designing and manufacturing test, measurement and monitoring instruments, systems and solutions, and semiconductor and optical components. The company serves markets that include communications, electronics, life sciences and healthcare. The businesses comprising Agilent, a subsidiary of HP, had net revenues of more than $8.3 billion in fiscal year 1999.
Information about Agilent Technologies can be found on the Web at www.agilent.com.
Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "intend," "anticipate," "should," "planned," "estimated," and "potential," among others. These forward-looking statements are based on PE Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, PE Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of PE Biosystems businesses include but are not limited to (1) rapidly changing technology and dependence on new products; (2) sales dependent on customers' capital spending policies and government-sponsored research; (3) claims for patent infringement; (4) significant overseas operations; (5) future growth strategy; (6) earthquakes; and (7) other factors that might be described from time to time in PE Corporation's filings with the Securities and Exchange Commission. |
